Chemoproteomics in covalent cancer drug discovery
Authors:
Open Access
- 25 September 2026
- journal article
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Abstract
No abstract availableFunding Information
- Tour de Cure
- University of New South Wales
This publication has 90 references indexed in Scilit:
- Advances in reversible covalent kinase inhibitorsMedicinal Research Reviews, 2024
- SP3‐FAIMS Chemoproteomics for High‐Coverage Profiling of the Human Cysteinome**ChemBioChem, 2021
- Isotopically Labeled Desthiobiotin Azide (isoDTB) Tags Enable Global Profiling of the Bacterial CysteinomeAngewandte Chemie International Edition, 2019
- Covalent Inhibition in Drug DiscoveryChemMedChem, 2019
- Covalent Docking of Large Libraries for the Discovery of Chemical ProbesBiophysical Journal, 2014
- Conversion of Cysteine into Dehydroalanine Enables Access to Synthetic Histones Bearing Diverse Post‐Translational ModificationsAngewandte Chemie International Edition, 2012
- How Chemoproteomics Can Enable Drug Discovery and DevelopmentChemistry & Biology, 2012
- Early drug discovery and the rise of pharmaceutical chemistryDrug Testing and Analysis, 2011
- Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinaseBioorganic & Medicinal Chemistry Letters, 2010
- Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9)Bioorganic & Medicinal Chemistry Letters, 2010